Jaco A C van Bruggen

3PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Nov 14, 2025
Tumor-associated disruption of T cell receptor signaling: lessons across cancers with implications for CLL.

Carlota Lopez-Sanchez, Jaco A C van Bruggen, Arnon P Kater

|Jul 23, 2024
T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.

Jaco A C van Bruggen, Fleur S Peters, Morris Mes

|May 17, 2022
Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells.

J A C van Bruggen, G J W van der Windt, M Hoogendoorn

Pageof 1